{"title":"Biomarkers in Clinical Trials: From Cancer Researcher and Cancer Patient Perspective","authors":"","doi":"10.25163/angiotherapy.6313c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6313c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121042529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Developing Affordable Cancer Therapeutics in Low and Middle Income Countries","authors":"","doi":"10.25163/angiotherapy.637c","DOIUrl":"https://doi.org/10.25163/angiotherapy.637c","url":null,"abstract":"Over half the world’s cancers occur in Low-and-Middle-Income-Countries (LMICs), where cancer is a neglected disease. Despite significant advances in systemic anticancer therapy, many of these treatments are simple not available to the majority of the world’s cancer patients. For example, immunotherapy has changed the treatment paradigm for many cancer patients in developed countries, significantly prolonging survival and maintaining patient quality of life but at a cost that is currently unaffordable for many public health systems and patients in LMICs. We urgently need better solutions to treat patients more effectively, humanely and equitably. Drug discovery and novel drug development takes on average 10-15 years to go from bench to bedside at an average cost of USD1 billion. Repurposing of 'old' drugs for new indications can shorten this pathway substantially with significant cost savings. One strong drug repurposing candidate is artesunate, an antimalarial derived from traditional Chinese medicine that also displays anticancer properties. This drug is currently the subject of our drug repurposing programme which includes a number of cancers relevant to Malaysian needs including colorectal cancer, cervical cancer, nasopharyngeal cancer and Acute Myeloid Leukaemia. Alongside drug repurposing, platform technologies such as molecular pharming – using plants to grow cancer drugs, in particular immunotherapies and targeted monoclonal antibodies can also reduce the cost of cancer drug development significantly. Malaysia has the opportunity to lead on healthcare priorities facing LMICs, creating reverse linkage collaborations between Muslim countries through entities such as the Islamic Development Bank (which now has a Center of Excellence for Science, Technology and Innovation) in Kuala Lumpur and local governments. This also represents opportunities for technology transfer and halal sector manufacturing. Collaboration is urgently needed between academia, clinicians, patient advocate groups, governments, non-governmental stakeholders, regulators and responsible pharma to ensure equitable access to affordable cancer therapeutics for patients globally.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131100505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Elucidating the Transcriptional Regulation and Chemosensitivity Efficacy of Terminal Differentiation Induced Non-Coding RNA (TINCR) Driver Regulator in Triple-Negative Breast Cancer (TNBC)","authors":"","doi":"10.25163/angiotherapy.6318c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6318c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114563599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeted Delivery of Cisplatin Using RGD-Modified ZIF-90 as Delivery Vehicle","authors":"","doi":"10.25163/angiotherapy.6314c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6314c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"202 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133878993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emerging Immuno-cellular Therapy in the Treatment of Diffuse Large B-cell Lymphoma","authors":"","doi":"10.25163/angiotherapy.6311c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6311c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121057169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2nd International Scientific Conference of the The Malaysian Association for Cancer Research (MACR)","authors":"","doi":"10.25163/angiotherapy.631c","DOIUrl":"https://doi.org/10.25163/angiotherapy.631c","url":null,"abstract":"The Malaysian Association for Cancer Research (MACR) is proud to organize the second instalment of MACR International Scientific Conference (MSC) in partnership with Malaysian Oncological Society (MOS) and local Public & Private universities. MSC aims to provide a major convening platform for cancer research communities based locally and abroad. This two-day conference is expected to open up avenues for meaningful collaboration at the regional and global levels to promote cancer drug discovery and development through integrative research.The topics this conference will cover include but are not limited to: Novel cancer drug target identification, New cancer drug discoveries, Translational cancer medicine, Clinical trials of new cancer drugs, Diagnostic and prognostic values of new cancer markers, Cancer prevention, and Precision oncology. Download the published abstract (please click on the PDF file right side of this abstract)","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124513551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development and Characterisation of Zerumbone-Superparamagnetic Iron Oxide Nanoparticle Co-Loaded Nanostructured Lipid Carriers as A Potential Treatment for Breast Cancer","authors":"","doi":"10.25163/angiotherapy.6321c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6321c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132028917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cytotoxicity Effects of Selected Flavonoids in Human Ovarian Cancer Cells","authors":"","doi":"10.25163/angiotherapy.6317c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6317c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134227985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular Modelling Analysis of Squamocin as Potential BCL-XL Anti-apoptotic Protein Inhibitor","authors":"","doi":"10.25163/angiotherapy.6316c","DOIUrl":"https://doi.org/10.25163/angiotherapy.6316c","url":null,"abstract":"","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132214939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ferritin and High Sensitivity C-Reactive Protein (hs-CRP) may predict the COVID-19 patient’s fate","authors":"Z. A. Kheudhier, A. Mossa","doi":"10.25163/angiotherapy.625319","DOIUrl":"https://doi.org/10.25163/angiotherapy.625319","url":null,"abstract":"Objective: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide. Clinical outcomes and disease severity are still unknown and can be difficult to predict. In this study, we perform a cross-sectional observational study to investigate the clinical characteristics of ferritin and high sensitivity C-reactive protein status of patients infected with COVID-19 that may predict the COVID-19 patient’s fate. Methods: A total of 106 patients (56 males and 50 females, their ages ranging from 19 to 70 years) who were confirmed to have COVID-19 by real-time RT-PCR were recruited in this study. Blood samples were withdrawn, and biochemical tests (serum ferritin and C-reactive protein) were performed. The gained data were analyzed using GraphPad Prism software. Results: Overall, the findings showed that ferritin and C-reactive protein were increased from day 1 to day 7 and then decreased on day 14 after diagnosis in patients who are released after full recovery. While they still dramatically increased from day 1 to day 7 to day 14 in those who moved to the intensive care unit or died by day 14. No gender-based differences were noted. Conclusions: These findings suggest that the patient’s fate and disease severity can be predicted at day 7 based on these two biomarkers.","PeriodicalId":154960,"journal":{"name":"Journal of Angiotherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128488017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}